Literature DB >> 1356154

Characterization of [3H]quinpirole binding to D2-like dopamine receptors in rat brain.

B Levant1, D E Grigoriadis, E B DeSouza.   

Abstract

The putative D2 dopamine receptor agonist quinpirole (LY 171,555) is the most widely used D2 agonist in in vivo and in vitro studies of D2 receptor-mediated effects. In addition, quinpirole may have even higher affinity for the recently described D3 dopamine receptor. The present study describes the in vitro binding properties of newly developed [3H]quinpirole in rat brain. [3H]Quinpirole binding was characterized in striatal membrane homogenate preparations using a filtration assay. Nonspecific binding was defined by 1 microM (+)-butaclamol. Specific [3H]quinpirole binding was saturable, and dependent on temperature, membrane concentration, sodium concentration and guanine nucleotides. Saturation analysis revealed high affinity binding characteristics (KD = 2.3 +/- 0.3 nM) which were confirmed by association-dissociation kinetics. The pharmacological profile of [3H]quinpirole binding in striatum was: (-)-N-n-propylnorapomorphine (+/-)-2-amino-6,7-dihydroxyl-1,2,3,4-tetrahydronaphthalene greater than or equal to quinpirole greater than apomorphine greater than bromocriptine greater than dopamine greater than SKF 38393 much greater than 5-hydroxytryptamine for putative dopamine agonists; spiperone greater than (+)-butaclamol greater than haloperidol greater than (-)-sulpiride greater than clozapine greater than SCH 23390 much greater than cinanserin for antagonists. [3H]Quinpirole binding exhibited stereoselectivity: (-)-sulpiride greater than (+)-sulpiride and (+)-butaclamol greater than (-)-butaclamol. This pharmacological profile is similar, though-not identical, to that observed for [3H] spiperone-labeled D2 receptors. The regional distribution of [3H]quinpirole binding sites roughly paralleled the distribution of [3H]spiperone binding sites, with greatest densities present in the striatum, nucleus accumbens and olfactory tubercles.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1356154

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  32 in total

1.  Dopamine D(2) receptor function is compromised in the brain of the methionine sulfoxide reductase A knockout mouse.

Authors:  Derek B Oien; Andrea N Ortiz; Alexander G Rittel; Rick T Dobrowsky; Michael A Johnson; Beth Levant; Stephen C Fowler; Jackob Moskovitz
Journal:  J Neurochem       Date:  2010-03-31       Impact factor: 5.372

2.  Chronic valproate treatment blocks D2-like receptor-mediated brain signaling via arachidonic acid in rats.

Authors:  Epolia Ramadan; Mireille Basselin; Ameer Y Taha; Yewon Cheon; Lisa Chang; Mei Chen; Stanley I Rapoport
Journal:  Neuropharmacology       Date:  2011-08-03       Impact factor: 5.250

Review 3.  Inflammation and cancer-related fatigue: mechanisms, contributing factors, and treatment implications.

Authors:  Julienne E Bower; Donald M Lamkin
Journal:  Brain Behav Immun       Date:  2012-07-06       Impact factor: 7.217

4.  Imaging Agonist-Induced D2/D3 Receptor Desensitization and Internalization In Vivo with PET/fMRI.

Authors:  Christin Y Sander; Jacob M Hooker; Ciprian Catana; Bruce R Rosen; Joseph B Mandeville
Journal:  Neuropsychopharmacology       Date:  2015-09-21       Impact factor: 7.853

5.  Influence of cocaine history on the behavioral effects of Dopamine D(3) receptor-selective compounds in monkeys.

Authors:  B L Blaylock; R W Gould; A Banala; P Grundt; R R Luedtke; A H Newman; M A Nader
Journal:  Neuropsychopharmacology       Date:  2011-02-02       Impact factor: 7.853

Review 6.  Agonist high- and low-affinity states of dopamine D₂ receptors: methods of detection and clinical implications.

Authors:  Jan-Peter van Wieringen; Jan Booij; Vladimir Shalgunov; Philip Elsinga; Martin C Michel
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2012-12-09       Impact factor: 3.000

7.  Quantitative unit classification of ventral tegmental area neurons in vivo.

Authors:  Wei Li; William M Doyon; John A Dani
Journal:  J Neurophysiol       Date:  2012-02-29       Impact factor: 2.714

8.  Clorgyline-induced modification of behavioral sensitization to quinpirole: effects on local cerebral glucose utilization.

Authors:  Toni L Richards; Thomas L Pazdernik; Beth Levant
Journal:  Brain Res       Date:  2007-05-31       Impact factor: 3.252

9.  Quantitative comparison of functional screening by measuring intracellular Ca2+ with radioligand binding at recombinant human dopamine receptors.

Authors:  Matthias U Kassack
Journal:  AAPS PharmSci       Date:  2002

10.  Basal local cerebral glucose utilization is not altered after behavioral sensitization to quinpirole.

Authors:  Toni L Richards; Thomas L Pazdernik; Beth Levant
Journal:  Neurosci Lett       Date:  2007-10-18       Impact factor: 3.046

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.